Voyager Therapeutics Inc
VYGR3.105USD
+0.145+4.90%
交易中 （美東）報價延遲15分鐘
171.43M總市值
虧損本益比TTM
關於 Voyager Therapeutics Inc 公司
Voyager Therapeutics, Inc. 是一家專注於推進神經遺傳藥物的生物技術公司。該公司的研發線包括針對阿爾茨海默病、肌萎縮側索硬化症 (ALS)、帕金森病和多種其他中樞神經系統疾病的項目。該公司的許多項目都源自其 TRACER AAV 衣殼發現平臺，該平臺用於生成新型衣殼並識別相關受體，從而有可能使基因藥物在靜脈注射後實現高腦滲透。該公司的研發線項目均處於臨牀前開發階段，包括抗 Tau 抗體 (VY-TAU01)、SOD1 沉默基因治療項目、Tau 沉默基因治療項目、矢量化抗澱粉樣蛋白抗體早期研究項目、弗裏德賴希共濟失調項目：VY-FXN01、GBA1 基因置換項目、HD 項目等。VY-TAU01 用於治療阿爾茨海默病。 SOD1沉默基因治療計劃用於治療 ALS。
公司簡介
公司代碼VYGR
公司名稱Voyager Therapeutics Inc
上市日期Nov 11, 2015
CEODr. Alfred W. Sandrock, M.D., Ph.D.
員工數量172
證券類型Ordinary Share
年結日Nov 11
公司地址75 Hayden Avenue
城市LEXINGTON
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02421
電話18572595340
網址https://www.voyagertherapeutics.com/
公司代碼VYGR
上市日期Nov 11, 2015
CEODr. Alfred W. Sandrock, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Alfred W. Sandrock, M.D., Ph.D.
Dr. Alfred W. Sandrock, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
134.26K
-25.20%
Ms. Robin Swartz
Ms. Robin Swartz
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
84.49K
+250.80%
Dr. Toby Ferguson, M.D., Ph.D.
Dr. Toby Ferguson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.91K
-85.17%
Dr. Glenn F. Pierce, M.D., Ph.D.
Dr. Glenn F. Pierce, M.D., Ph.D.
Independent Director
Independent Director
21.79K
--
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Director
Director
2.91K
--
Dr. George A. Scangos, Ph.D.
Dr. George A. Scangos, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Todd Carter, Ph.D.
Dr. Todd Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. James Arthur (Jim) Geraghty, J.D.
Mr. James Arthur (Jim) Geraghty, J.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Alfred W. Sandrock, M.D., Ph.D.
Dr. Alfred W. Sandrock, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
134.26K
-25.20%
Ms. Robin Swartz
Ms. Robin Swartz
Chief Operating Officer, Chief Business Officer
Chief Operating Officer, Chief Business Officer
84.49K
+250.80%
Dr. Toby Ferguson, M.D., Ph.D.
Dr. Toby Ferguson, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.91K
-85.17%
Dr. Glenn F. Pierce, M.D., Ph.D.
Dr. Glenn F. Pierce, M.D., Ph.D.
Independent Director
Independent Director
21.79K
--
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Director
Director
2.91K
--
Dr. George A. Scangos, Ph.D.
Dr. George A. Scangos, Ph.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Neurocrine Biosciences Inc
15.50%
Armistice Capital LLC
9.82%
EcoR1 Capital, LLC
7.08%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.80%
Other
55.22%
持股股東
持股股東
佔比
Neurocrine Biosciences Inc
15.50%
Armistice Capital LLC
9.82%
EcoR1 Capital, LLC
7.08%
BlackRock Institutional Trust Company, N.A.
6.58%
The Vanguard Group, Inc.
5.80%
Other
55.22%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
23.35%
Investment Advisor
20.26%
Hedge Fund
16.83%
Corporation
15.50%
Research Firm
2.35%
Individual Investor
1.32%
Bank and Trust
0.57%
Pension Fund
0.50%
Venture Capital
0.03%
Other
19.30%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
301
44.67M
80.73%
-3.34M
2025Q1
320
44.96M
81.54%
-6.59M
2024Q4
316
44.59M
81.64%
-6.62M
2024Q3
302
45.03M
82.56%
-8.55M
2024Q2
298
47.92M
88.05%
-2.79M
2024Q1
277
45.43M
90.18%
+7.85M
2023Q4
257
36.58M
85.81%
-1.09M
2023Q3
248
36.63M
86.15%
-1.09M
2023Q2
242
36.26M
85.84%
+5.02M
2023Q1
252
33.40M
79.73%
+1.16M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Neurocrine Biosciences Inc
8.58M
15.5%
--
--
Apr 07, 2025
Armistice Capital LLC
5.44M
9.82%
+40.00K
+0.74%
Mar 31, 2025
EcoR1 Capital, LLC
3.92M
7.08%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.64M
6.58%
+9.42K
+0.26%
Mar 31, 2025
The Vanguard Group, Inc.
3.21M
5.8%
-4.36K
-0.14%
Mar 31, 2025
Farallon Capital Management, L.L.C.
2.57M
4.65%
--
--
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.50M
2.7%
+115.67K
+8.38%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.43M
2.58%
+56.45K
+4.12%
Mar 31, 2025
Vestal Point Capital, LP
1.25M
2.26%
+19.42K
+1.58%
Mar 31, 2025
Erste Asset Management GmbH
1.12M
2.02%
+58.41K
+5.52%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.51%
Tema Neuroscience and Mental Health ETF
0.42%
iShares Neuroscience and Healthcare ETF
0.34%
iShares Health Innovation Active ETF
0.06%
WisdomTree US SmallCap Fund
0.03%
WisdomTree US SmallCap Quality Growth Fund
0.03%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
查看更多
Invesco NASDAQ Future Gen 200 ETF
佔比0.51%
Tema Neuroscience and Mental Health ETF
佔比0.42%
iShares Neuroscience and Healthcare ETF
佔比0.34%
iShares Health Innovation Active ETF
佔比0.06%
WisdomTree US SmallCap Fund
佔比0.03%
WisdomTree US SmallCap Quality Growth Fund
佔比0.03%
iShares Micro-Cap ETF
佔比0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.02%
Invesco Nasdaq Biotechnology ETF
佔比0.02%
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
